Question 1

Am I eligible for this study based on my current treatment and cancer status?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib) clinical trial (NCT02133508). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Tarceva compare to other second-line treatments for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib) clinical trial (NCT02133508). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of continuing with Tarceva?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib) clinical trial (NCT02133508). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during this observational study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib) clinical trial (NCT02133508). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect in terms of follow-up appointments and tests?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib) clinical trial (NCT02133508). Contact the study team or your healthcare provider for specific answers.

Question 6

How might the results of this study impact my future treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib) clinical trial (NCT02133508). Contact the study team or your healthcare provider for specific answers.

What this study is about